TABLE 2.
Treatment patterns overall and by relapse status
| Treatment characteristics | Overall n = 456 | Relapse n = 206 | No relapse n = 250 | p value |
|---|---|---|---|---|
| Surgery type, n (%) | 0.7024 | |||
| Lobectomy or bilobectomy | 368 (80.7) | 168 (81.6) | 200 (80.0) | |
| Pneumonectomy | 42 (9.2) | 18 (8.7) | 24 (9.6) | |
| Wedge or segmentectomy | 20 (4.4) | 9 (4.4) | 11 (4.4) | |
| Other a | 26 (5.7) | 11 (5.3) | 15 (6.0) | |
| Adjuvant treatment received | 0.4051 | |||
| Chemotherapy without radiation | 369 (80.9) | 163 (79.1) | 206 (82.4) | |
| Chemotherapy with sequential radiation | 61 (13.4) | 28 (13.6) | 33 (13.2) | |
| Chemotherapy with concurrent radiation | 26 (5.7) | 15 (7.3) | 11 (4.4) | |
| Treatments received | ||||
| Chemotherapy without radiation, n (%) | 369 (80.9) | 163 (79.1) | 206 (82.4) | |
| Chemotherapy duration, months, median (range) b | 2.1 (0.0,14.6) | 2.2 (0.0,14.6) | 2.1 (0.0,5.6) | 0.1790 |
| Treatments received, n (%) | ||||
| Cisplatin/vinorelbine | 118 (32.0) | 55 (33.7) | 63(30.6) | |
| Carboplatin/paclitaxel | 95 (25.7) | 43 (26.4) | 52(25.2) | |
| Cisplatin/pemetrexed | 60 (16.3) | 27 (16.6) | 33(16.0) | |
| Carboplatin/pemetrexed | 31 (8.4) | 12 (7.4) | 19(9.2) | |
| Other c | 152 (33.3) | 137 (33.5) | 167 (33.2) | |
| Chemotherapy with sequential radiation d | 61 (13.4) | 28 (13.6) | 33 (13.2) | |
| Chemotherapy duration, months, median (range) b | 2.1 (0.0,4.2) | 2.2 (1.0,4.2) | 2.1 (0.0,4.1) | |
| Treatments received, n (%) | ||||
| Carboplatin/paclitaxel | 24 (39.3) | 10 (35.7) | 14 (42.4) | |
| Cisplatin/vinorelbine | 17 (27.9) | 8 (28.6) | 9 (27.3) | |
| Cisplatin/pemetrexed | 10 (16.4) | 4 (14.3) | 6 (18.2) | |
| Cisplatin/etoposide | 4 (6.6) | 1 (3.6) | 3 (9.1) | |
| Other c | 6 (9.8) | 5 (17.9) | 1 (3.0) | |
| Chemotherapy with concurrent radiation e | 26 (5.7) | 15 (7.3) | 11 (4.4) | |
| Chemotherapy duration, months, median (range) | 2.1 (0.8,5.4) | 2.1 (1.0,5.4) | 2.1 (0.8,4.8) | 0.7950 |
| Treatments received, n (%) | ||||
| Carboplatin/paclitaxel | 14 (53.8) | 8 (53.3) | 6 (54.5) | |
| Cisplatin/etoposide | 4 (15.4) | 1 (6.7) | 3 (27.3) | |
| Cisplatin/pemetrexed | 2 (7.7) | 2 (13.3) | 0 (0.00) | |
| Cisplatin/vinorelbine | 2 (7.7) | 2 (13.3) | 0 (0.00) | |
| Other c | 4 (15.4) | 2 (13.3) | 2 (18.2) | |
a
Includes combination procedures and/or mediastinal resection or lymphadenectomy.
b
Treatment duration lasting only 1 day is presented as 0.0 months.
c
Adjuvant treatments used in <5.0% of the overall population.
d
Sequential radiation occurred when radiation dates were within 90 days of chemotherapy dates.
e
Concurrent radiation occurred when dates of chemotherapy and radiation overlapped.